

Hana Biosciences (S. San Francisco, CA, USA) has announced the appointment of **Lyn Wiesinger** (left) to its board of directors. Ms. Wiesinger has over 20 years of experience in the pharmaceutical industry, most recently serving as senior vice president of marketing and market development at Vicuron Pharmaceuticals. She also held leadership positions at Bristol-Myers Squibb, Pfizer and Rhône-Poulenc Rorer.

"We are extremely pleased to have Ms. Wiesinger, a seasoned pharmaceutical and biotech industry veteran, join our board of

directors," says Mark Ahn, president and CEO. "Her wealth of industry management, development and commercial expertise make her an excellent addition to Hana's board."

Alkermes (Boston) has announced that as of April 1 **David Broecker**, its president and COO, will ascend to the position of CEO, succeeding **Richard Pops**. Mr. Pops, who has served as CEO since 1991, will succeed Alkermes founder **Michael Wall** as chairman; Mr. Wall will become chairman emeritus. Mr. Broecker, who joined the company in 2001, will retain the title of president.

Innovive Pharmaceuticals (New York) has named **Angelo De Caro** to serve on the company's board of directors and audit committee. Mr. De Caro brings more than four decades of experience in finance and operations, serving as chairman and CEO of Patriot National Bancorp since 2001 and as a director of the company since 1999. In addition, he served as general partner and senior financial officer at Goldman Sachs for more than ten years.

Commonwealth Biotechnologies (Richmond, VA, USA) has named **Paul D'Sylva** as CEO and a director. His appointment follows Commonwealth's acquisition of Mimotopes Pty. Ltd. for which Dr. D'Sylva served as managing director and as a member of its board of directors.

Technologie Biolactis (Montreal, PQ, Canada) has elected **Achim Kaufhold** to its board of directors. Until 2006, he was chief medical officer and vice president of development at Chiron and a member of the executive committee at Chiron Vaccines. He joined Chiron from Berna Biotech, where he served as chief medical officer, head of research, product and business development.

Michael J. Knauf has been appointed to the position of vice president and general manager, bioindustrials at Codexis (Redwood City, CA, USA). He joins Codexis from Lallemand Specialties, where he was general manager of the ethanol technology business unit. Previously, he served for nearly 20 years with Genencor, where he rose to director and industry manager for fermentation alcohol enzymes.

OXIGENE (Waltham, MA, USA) has announced that **John A. Kollins** has joined the company as senior vice president and chief business officer. Mr. Kollins previously held positions as chief business officer at CovX and vice president, business development at Renovis.

Thomas H. McLain has resigned from his position as chairman, CEO and president of Nabi Pharmaceuticals (Boca Raton, FL, USA). He resigned shortly after reportedly working out a deal to accommodate Third Point, a hedge fund investor that had been harshly critical of McLain's performance. Nabi board member Leslie Hudson has been appointed interim CEO and president for a six-month term and Geoffrey F. Cox, a member of the board since 2000, has been named nonexecutive chairman of the board of directors.

Privately held Anthera Pharmaceuticals (San Mateo, CA, USA) has appointed **James E. Pennington** to the position of executive vice president and chief medical officer. Dr. Pennington has over 20 years of pharmaceutical industry experience, most recently at

CoTherix, where he served in the same position. Previously, he was executive vice president, medical and scientific affairs and chief medical officer of InterMune.

Seattle Genetics (Bothell, WA, USA) has announced that **Thomas C. Reynolds** has joined the company as chief medical officer. Dr. Reynolds was most recently vice president, medical affairs at Zymogenetics.



Kelli Richard (left) has been appointed to the position of vice president, finance and chief accounting officer of Invitrogen. Ms. Richard joined the company in August 2005 after previously

serving as vice president, accounting and reporting and principal accounting officer at Gateway. Additionally, Invitrogen has named **Per Peterson** to its board of directors. Dr. Peterson recently retired as chairman of R&D at Johnson & Johnson, where he held responsibility for the corporate office of science and technology, the enterprise-wide R&D council, and J&J's cell therapy research activities.

Robert P. Wayman, former executive vice president and CFO at Hewlett-Packard, has been elected to Affymetrix's (Santa Clara, CA, USA) board of directors. Mr. Wayman joined HP in 1969 as a cost accountant, holding a variety of positions before being named CFO in 1984. He served on HP's board from 1993–2002 and again from February 2005 until his retirement in December. Mr. Wayman is also a director of Conway and Sybase.

The Burnham Institute for Medical Research (La Jolla, CA, USA) has appointed **Robert H. Zaugg** to the position of vice president, business development. Dr. Zaugg has worked as an independent consultant, served as interim CEO of several California biotech companies including DermAegis and Optime Therapeutics, and previously held the positions of general manager of GTS Proteomics and vice president of business development at Vical.